ERBB2 and gastric cancer: In solid cancer, ADCs targeting human epidermal growth factor receptor 2 (HER2), such as trastuzumab emtansine and trastuzumab deruxtecan, showed favorable outcomes in HER2-positive breast or gastric cancer [7,8,9].